Endpoints and patient stratification in clinical trials for alcoholic hepatitis - Université de Lille Accéder directement au contenu
Article Dans Une Revue Journal of Hepatology Année : 2019

Endpoints and patient stratification in clinical trials for alcoholic hepatitis

Résumé

In some areas of medicine the clinical development pathway through phase II and III clinical trials has been well mapped out and refined through extensive experience. In contrast, a number of key questions remain unanswered in the development of novel therapeutics for alcoholic hepatitis. The use of mortality as an endpoint in phase II clinical trials will potentially restrict the appeal of this therapeutic area for pharmaceutical companies, as the number of patients required for adequately powered clinical trials becomes impractical. Herein, we discuss alternative endpoints and conclude that dynamic assessment of liver function is the most pragmatic option in early stage studies. Stratification based on disease severity should be applied to avoid uneven distribution of patients with substantially differing mortality risks. Consensus on early phase trial design would help to facilitate new therapeutic development in this area of high unmet medical need.

Dates et versions

hal-04318455 , version 1 (01-12-2023)

Identifiants

Citer

Philippe Mathurin, Mark Richard Thursz. Endpoints and patient stratification in clinical trials for alcoholic hepatitis. Journal of Hepatology, 2019, Journal of hepatology, 70, pp.314-318. ⟨10.1016/j.jhep.2018.11.005⟩. ⟨hal-04318455⟩

Collections

RIIP UNIV-LILLE
10 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More